This IR Book (hereafter the “Book”) of MiCo BioMed (the “Company”) has been published in order to provide information

to institutional investors and

enable them to understand the Company’s business. “Forward-looking” information contained in the Book has not been confirmed separately.

Certain information set forth in this Book contains “forward-looking information” regarding the Company’s future business and financial performances,
explained using terminologies like “Expected”, “Outlook”, “Plan”, “Forecast”, and “(E)”.

Such “forward-looking information” essentially contains uncertainties and the actual business results may vary substantially from what has been reported
or implied.

Also, projections of the Company’s future performance is based on what the management believes to be a reasonable assumption as of now, taking into
account the current market situation and the Company’s business positioning and therefore is subjected to changes of market environment and business
strategies. Also the Company may alter or omit the content of this website without prior notice.

Neither the Company nor its employees bears liability in relation to the use of any information posted on this Book and any loss claimed to have occurred
in relation to the use.
The Book is not intended to make a solicitation or to offer to subscribe, buy or sell any securities. Please be aware that no particular information
contained in the Book can be a basis for investment-related decisions.
Any decisions related to purchasing securities should be solely based on the publicly disclosed financial reports that the Company has submitted to
Financial Supervisory Authority.

The book can be used for nonprofit purposes without changing the contents (must identify the source). Please note that unauthorized distribution and
copying may be subjected to legal restrictions.
Ever since MiCo BioMed was founded in 2009, we have been focusing on one
mission statement: healthcare for everyone, everywhere. We work hard knowing
that molecular diagnostics is critical in achieving global health and happiness.

We are striving to overcome the limits of existing devices and reagents with our
Lab-On-A-Chip based technology so we can carry out POCT (Point-Of-Care-
Testing) quickly and accurately.

Recently we merged with other companies in order to expand our line-up of

Products. Now specializing in biochemical and immunological diagnostics, we are
growing and evolving to be the leader in the global POCT market.

We deeply appreciate your interest and support for our company.

 First Outbreak in Korea

New viruses continue to emerge and threaten humanity

75%
(Other companies’ devices need 75 seconds,
taking 15 times longer)
Others
 804

65
* Open Reagents : Applicable to widely-used devices of main players such as Roche
Cholesterol Hemoglobin
36
LB Asset Management 182,586 1.0

Others 12,785,151 64.8